Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

The Open COVID Pledge

By Tim Wright of Fladgate LLP on May 6, 2020
Email this postTweet this postLike this postShare this post on LinkedIn

Intellectual property rights are – by definition – monopolistic. How, then, can researchers, charities and NGOs collaborate with business in the development of new technologies to control and eradicate COVID-19?

The Pledge

The Open COVID Pledge[1] is intended to encourage business and academia to pledge to make their intellectual property (IP) available free of charge for use in ending the COVID-19 pandemic and minimising the impact of the disease. The Pledge was developed by the Open COVID Coalition, an international group of scientists and lawyers who seek to accelerate the rapid development and deployment of diagnostics, vaccines, therapeutics, medical equipment and software solutions.

Getting involved

There are two ways of getting involved with the Pledge, namely “Support” and “Make”.

Supporting the Pledge – an expression of institutional support without legal obligation.

Making the Pledge – a promise to make some or all of its IP available for use in the fight against COVID-19.

If an organisation decides to “Make the Pledge” it should make a public statement to this effect on its website, issue an office press release, and notify the Open COVID Coalition. It must also publish a licence which sets out the terms and conditions on which such IP is made available.

In Making the Pledge in this way, the IP owner makes a binding promise which contains the grant of a license. In other words, the pledgor gives permission to others to rely on its promise (its Pledge) with legal force, notwithstanding the absence of a written contract, and to start to make and sell their own products based on the pledgor’s IP.

Companies such as Amazon, Facebook, Hewlett Packard Enterprise, IBM, Microsoft, Sandia National Laboratories and Uber have all Made the Pledge.

IP Licence

The IP owner must either (a) adopt one of three standard Open COVID Licenses (selecting the appropriate version depending on whether the licence should cover patents and copyright or just patents, and how long it should last), or (b) issue custom licence terms which must be at least as permissive as the Open COVID Licenses. In either case, no financial charge can be imposed, whatsoever.

The standard Open COVID Licenses grant the right to make, use, sell and otherwise exploit the IP in the fight against COVID-19. This includes, without limitation, diagnostics, vaccines, therapeutics and medical equipment. The license is simply a grant of legal rights.  The licence terms do not require the pledgor to provide materials, cell lines, prototypes, designs, plans, data, trial results, software or anything else, nor do they require any cooperation, training, technical assistance or consultation by the pledgor, or reporting or consultation by the licensee. It is open to the parties to negotiate a fuller cooperative arrangement (which can include compensation) if desired.

No Grant Back of Rights

It should be noted that the licence granted under the Open COVID Licenses is one-way. There is no licence-back of rights to the IP owner. The Open COVID Coalition state that, whilst this may seem imbalanced, unfair and inequitable, they believe it to be the best way of achieving the greatest adoption of the licence on a global basis.

No right to subcontract

Sublicensing is not permitted under the terms of the license. This is to ensure that all rights flow from the original IP holder and establishes a direct relationship between the IP holder and the user of the IP rights for purposes of enforcement, defensive suspension and other purposes.

Next steps

IP rights holders need to decide if they are licensing patents alone, or with copyright; they then simply need to consider what form of licence they want to use (or whether they need to prepare their own compatible form of licence), and notify the Open COVID Coalition so that their participation can be recorded and publicised.

IP rights holders that want to make the Pledge do not need to identify the specific IP that could be used, as the standard licences do not seem to require this.  Before committing themselves to the Pledge, however, we would recommend that IP owners should check that the grant of licences under the Pledge will not breach any exclusivity obligations which may be owed to existing IP licensees. If there is a need to restrict which IP is covered by the Pledge, then a custom form of licence will need to be used.

[1] https://opencovidpledge.org

Photo of Tim Wright of Fladgate LLP Tim Wright of Fladgate LLP

Tim Wright is a partner in the corporate department at Fladgate.

He specialises in commercial, outsourcing and technology transactions across various sectors such as banking, insurance, healthcare and technology. Services include outsourcing, cloud computing, digital platforms and e-commerce, web development and hosting, software…

Tim Wright is a partner in the corporate department at Fladgate.

He specialises in commercial, outsourcing and technology transactions across various sectors such as banking, insurance, healthcare and technology. Services include outsourcing, cloud computing, digital platforms and e-commerce, web development and hosting, software development and licensing, system integration projects, business transformation and digital projects, joint ventures, artificial intelligence and robotic process automation contracts, and wide-ranging procurement, commercial contracts and privacy issues.

Tim has acted for a number of pharmaceutical, banking and insurance companies, including GlaxoSmithKline, Dr. Reddy’s Laboratories, Sumitomo Dainippon Pharma, UBS, BNP Paribas, Cooperative Financial Services, Old Mutual, RSA, Phoenix Life, AXIS Capital, UBS and Goldman Sachs, as well as service providers such as Aon Hewitt, HCL Insurance, Storm Technologies, Company Watch and DST Systems, delivering a broad range of outsourcing and technology deals including information technology, facilities management, pensions administration, employee benefits administration, logistics, finance and accounting, and HR, as well as cloud computing, data processing agreements, and Workday, ERP (SAP, Oracle) and Office 365 implementations.

Since 2009, he worked extensively with GlaxoSmithKline on its global integrated facilities management outsourcing arrangements which has included strategy, extensive negotiations, scope expansions, service level agreements, service changes and re-procurements with GSK’s key FM vendors including CBRE and Sodexo.

Tim is a member of the Law Society of England & Wales, the Law Society of Ireland, ITechLaw, the Global Sourcing Association, the International Bar Association and the Society for Computers & Law.

He qualified in 1992, joining Fladgate in January 2019 from Pillsbury Winthrop Shaw Pittman LLP. Tim is also qualified in Ireland.

Read more about Tim Wright of Fladgate LLPEmailTim's Linkedin Profile
Show more Show less
  • Posted in:
    Intellectual Property
  • Blog:
    ILN IP Insider
  • Organization:
    International Lawyers Network
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo